YOYusuke Okada

Yusuke Okada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yusuke Okada has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Statin use and risk of amyotrophic lateral sclerosis: An active-comparator, new-user cohort study

    by Yusuke Okada, Satoru Morimoto, Shinichi Takahashi, Hideyuki Okano, Hisashi Urushihara

    Importance: Elevated circulating low-density lipoprotein (LDL) cholesterol is associated with an increased risk of amyotrophic lateral sclerosis (ALS) onset. Previous studies have explored the relationship between statin use and ALS onset. However, findings have been inconsistent, potentially due to methodological limitations, such as confounding by indication, and failure to account for baseline differences in LDL cholesterol levels. Objective: To compare the risk of ALS onset between new users of statins and ezetimibe among patients with hypercholesterolemia. Design: Active-comparator, new-user cohort study using inverse probability of treatment–weighted Cox proportional hazards models. The study period spanned April 2012 to February 2024. Setting: Two administrative claims databases in Japan. Participants: Patients with hypercholesterolemia who newly initiated statins or ezetimibe, and patients with dyslipidemia who newly initiated fibrates. All participants were required to have at least 365 days of baseline observation and no prior diagnosis of ALS. Exposure(s): Statin use compared with ezetimibe use. Fibrate use was assessed for benchmarking. Main Outcome(s) and Measure(s): The outcome was incident ALS, defined as a first definitive diagnosis of ALS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to compare ALS risk between statins and ezetimibe. Results: The study included 607,292 statin users (median [IQR] age, 61 [51–71] years; 51.4% male), 26,963 ezetimibe users (median [IQR] age, 59 [49–71] years; 50.1% male), and 114,871 fibrate users (median [IQR] age, 61 [51–71] years; 51.4% male). The incidence rate per 100,000 person-years of ALS was 6.8, 15.9, and 4.3, respectively. Statin use was associated with a lower hazard of ALS onset than ezetimibe use (adjusted HR [95% CI]: 0.42 [0.19–0.92]). The mean (SD) LDL cholesterol immediately prior to treatment initiation was 171.0 (28.6) mg/dL in the statin group and 162.8 (30.8) mg/dL in the ezetimibe group. After treatment, mean LDL cholesterol levels decreased to and stayed below 140 mg/dL in both groups. Conclusions and Relevance: This study suggests that statins may lower the risk of ALS onset among patients with hypercholesterolemia. The mechanism underlying this association is not yet clear and may involve pathways beyond circulating LDL cholesterol reduction. Key points: Question: Does statin use lower the risk of amyotrophic lateral sclerosis (ALS) onset among patients with hypercholesterolemia? Findings: In this active-comparator, new-user cohort study of 607,292 statin users and 26,963 ezetimibe users with hypercholesterolemia, statin use was associated with a lower hazard of ALS onset compared with ezetimibe use. Prior to treatment initiation, mean LDL cholesterol levels were similar between statin and ezetimibe users. Meaning: These findings suggest that statins may lower the risk of ALS among patients with hypercholesterolemia.


  • Open Access

    Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID‐NET: A Cohort Study in Japan

    by Yusuke Okada, Kazuhiro Kajiyama, Maki Komamine, Takashi Ando, Tomoaki Hasegawa, Chieko Ishiguro, Takahiro Nonaka, Mariko Tsukuda, Yukari Iwasaki, Takahiro Ueda, et al.

    Risk assessment on thrombocytopenia by selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) is limited. An observational study with cohort design was conducted based on the MID‐NET for evaluating the risk of thrombocytopenia by SSRIs and SNRIs in patients with depression compared to paroxetine. The exposure group was categorized as each drug of SSRIs/SNRIs, SSRIs group (escitalopram, sertraline, fluvoxamine), SNRIs group (duloxetine, venlafaxine, milnacipran), or vortioxetine. We estimated the adjusted hazard ratio (aHR) of each drug compared to paroxetine for the risk of thrombocytopenia (platelet count < 100,000/mm3). More severe definitions were used in sensitivity analyses. In all, 4759 patients (median age: 49 years; 31.6% male) on SSRIs, 3440 patients (62 years; 38.6% male) on SNRIs, 12 patients (42.5 years; less than 83.4% male) on vortioxetine, and 2196 patients on paroxetine (62 years; 33.2% male) were included for analysis. Compared with paroxetine, the aHRs (95% confidence interval) of SSRIs group and SNRIs group were 1.14 (0.76–1.70) and 0.77 (0.48–1.21), respectively. Among SSRIs, sertraline and fluvoxamine showed a relatively higher point estimate of aHR > 1.0 (1.23 [95% confidence interval: 0.78–1.94] and 1.48 [0.87–2.51], respectively). The consistent results were also observed in the sensitivity analyses. The results suggest that the risk of thrombocytopenia by sertraline or fluvoxamine was comparable to that by paroxetine, known as having the risk of thrombocytopenia, leading to the revision of the sertraline package insert as a regulatory safety measure. Prescribers and clinicians may need to be vigilant to the possibility of sertraline‐induced thrombocytopenia in clinical practice.


  • Open Access

    New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug

    by Yusuke Okada, Takashi Ando, Fumitaka Takahashi, Kenichi Watanabe, Kazuhiro Kajiyama, Tomoaki Hasegawa, Satomi Inomata, Yuki Kinoshita, Shinya Watanabe, Yoshiaki Uyama

    Real‐world data play a key role in monitoring drug safety at the post‐marketing stage. However, challenges on how to rapidly and continuously obtain analytical results of many outcomes for drug safety signal monitoring still remain. We aimed to establish a rapid and continuous monitoring tool for drug safety assessment based on real‐world data in Japan. An automated process for a new‐user cohort design with customizable analytical conditions was developed. The customizable analytical conditions include exposure and control drugs, 46 outcomes related to liver and kidney functions, blood tests, biomarkers, and time period of interest. Statistical analyses were performed to evaluate the outcome status (present/absent) and calculate the adjusted hazard ratio, with a 95% confidence interval of exposure to control. We monitored the safety signals of an anti‐COVID‐19 drug (combination of tixagevimab and cilgavimab) and compared them with those of two controls (peramivir and the combination of casirivimab and imdevimab) to examine the practical utility of this new tool. Our study provided helpful information (e.g., new safety signals) on many outcomes at multiple time points, which could enhance the understanding of drug safety profiles soon after approval. Our function can be used to rapidly and continuously monitor drug safety signals and contribute to strengthening drug safety monitoring in Japan.


  • Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses

    by Yusuke Okada, Ken Inada, Manabu Akazawa

    Background: We compared the effectiveness of long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAs) in treating schizophrenia, focusing on whether the benefits of LAIs over OAs are evident even in the prevalent new user design and on effect heterogeneity. Methods: We conducted a prevalent new user cohort study using 2 administrative claims databases in Japan. We included patients with schizophrenia initiated on LAIs and propensity score–matched patients on OA. We compared the risks of psychiatric hospitalization and treatment discontinuation based on hazard ratios (HRs) using the Cox proportional hazards model. Effect heterogeneity was evaluated using subgroup analyses. Results: In total, 2520 patients using LAI and OA were identified as matched cohorts. Long-acting injectable antipsychotics were associated with a higher psychiatric hospitalization risk than OAs (HR, 1.41; 95% confidence interval [CI], 1.06–1.88) in the entire population; however, LAIs were associated with lower risk in the group with a low proportion of days covered and psychiatric hospitalization history (HR, 0.51; 95% CI, 0.30–0.89). Long-acting injectable antipsychotics were associated with a lower risk of treatment discontinuation than OAs (HR, 0.76; 95% CI, 0.66–0.87) in the entire population; in the subgroup analyses, a consistent trend was observed in all strata (LAIs had a lower risk). Conclusions: Using a prevalent new user design, this study confirmed that LAIs have an advantage regarding treatment continuity. Long-acting injectable antipsychotics had higher psychiatric hospitalization risk than OAs in the entire population; however, this study suggested the presence of effect heterogeneity due to psychiatric hospitalization history.

  • Open Access

    Trends in Research about “Paralympic Education” in the National English Literature

    by Yusuke Okada, So Nemoto, Yuji Chichii

    The purpose of this paper was to clarify future research subjects of “Paralympic Education” through examining research trends on “Paralympic Education” in journal articles published in English literature. As a result of analyzing 5 papers extracted through prescribed procedures from the analysis viewpoint of purpose, method and result (discussion), the following conclusions were drawn. As a research target of “Paralympic Education”, it was shown that it is necessary to examine not only the students who took the program but also the teachers who practiced it, for various para-education programs. As a method of “Paralympic Education”, it was shown that it was necessary to examine the changes in attitude toward persons with disabilities by using questionnaires such as CAIPE-R and AC. In addition, it was necessary to analyze not only changes before and after practice, but also based on sex and teaching experience, as well as contact experience with persons with disabilities and experience of taking “Paralympic Education”. From now on, by tackling these issues, improvement of research on “Paralympic Education” will be required.